Clinical trials: Refractory Metastatic Colorectal Cancer
Liver Metastasis, Pelvic Cancer
Photodynamic Therapy System for Patients With Refractory/Unresponsive Solid Tumors
This multi-center photodynamic therapy study plans to treat patients with large tumors in any superficial location, sarcoma, tumors of oral/oro-pharyngeal cavity, tumors with extensive pelvic involvement, or liver metastasis.
- Conditions
- Liver Metastasis, Pelvic Cancer, Head and Neck Cancer, Sarcoma
- Trial name
- NCT00028405
- Testing
- LS 11(Taporfin Sodium), Lumaflex Light Delivery Catheter
- Where
- 6 sites in United States
- Volunteers
- 48 people
- Sponsor
- Light Sciences LLC
Metastatic Colorectal Cancer
Phase I/II Study of Capecitabine Plus Aflibercept to Treat Metastatic Colorectal Cancer
The Primary Phase I objectives are to determine the recommended phase II dose for the capecitabine and aflibercept doublet combination; and to describe any dose limiting and non-dose limiting toxicities.
- Trial name
- X-TRAP (NCT01661972)
- Testing
- Capecitabine and aflibercept
- Where
- 2 sites in United States
- Volunteers
- 63 people
- Sponsor
- John Strickler, M.D.
Vaginal Cancer, Cervical Cancer
T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers
Background: The National Cancer Institute (NCI) Surgery Branch has developed an experimental therapy for treating patients with cancer that involves taking white blood cells from the patient, growing them in the laboratory in…
- Conditions
- Vaginal Cancer, Cervical Cancer, Anal Cancer, Penile Cancer
- Trial name
- NCT02280811
- Testing
- Fludarabine, Cyclophosphamide, E6 TCR
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Colorectal Cancer
Pemetrexed and Erlotinib for Metastatic Colorectal Cancer
Pemetrexed is a multitargeted antifolate, which primarily inhibits thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase in the folate-dependent metabolic process.
- Trial name
- NCT02723578
- Testing
- Pemetrexed, Erlotinib
- Where
- South Korea
- Volunteers
- 50 people
- Sponsor
- Yonsei University
Metastatic Colorectal Carcinoma, Recurrent Colon Carcinoma
TAS-102 and Oxaliplatin for the Treatment of Refractory Stage IV Colon Cancer
This phase II trial studies how well TAS-102 and oxaliplatin work in treating patients with stage IV colon cancer. Drugs used in chemotherapy, such as TAS-102 and oxaliplatin, work in different ways to stop the growth of tumor…
- Conditions
- Metastatic Colorectal Carcinoma, Recurrent Colon Carcinoma, Refractory Colorectal Carcinoma, Stage IV Colon Cancer AJCC v7
- Trial name
- NCT04294264
- Testing
- Oxaliplatin, Trifluridine and Tipiracil Hydrochloride
- Where
- 6 sites in United States
- Volunteers
- 50 people
- Sponsor
- Rutgers, The State University of New Jersey
Tumor, Colorectal Cancer
NKTR-102 in Combination With Cetuximab in Patients With Refractory Solid Tumors (Phase 2a) and Metastatic or Locally Advanced Colorectal Cancer (Phase 2b)
Study 07-PIR-02 is a Phase 2 study designed to evaluate the safety and efficacy of NKTR-102 (PEG-irinotecan) for the treatment of patients with colorectal cancer (CRC).
- Trial name
- NCT00598975
- Testing
- NKTR-102 100 mg/m2, NKTR-102 125 mg/m2, Cetuximab
- Where
- 4 sites in United States
- Volunteers
- 18 people
- Sponsor
- Nektar Therapeutics
Refractory Metastatic Colorectal Cancer
A Study Evaluating TAS-102 Plus Nivolumab in Patients With MSS CRC
A Phase 2 Study with Safety Lead-in, Evaluating TAS-102 Plus Nivolumab in Participants with Microsatellite Stable Refractory Metastatic Colorectal Cancer
- Trial name
- NCT02860546
- Testing
- TAS-102, nivolumab
- Where
- 3 sites in United States
- Volunteers
- 18 people
- Sponsor
- Taiho Oncology, Inc.
Colorectal Cancer Metastatic
Cetuximab, Irinotecan, Toripalimab in RAS/BRAF Wild-type Ultraselected Right-sided Colorectal Cancer Study
The objective of this clinical trial is to evaluate the efficacy and safety of cetuximab combined with PD-1 inhibitor and irinotecan in negative ultraselection RAS/BRAF wild-type refractory right-sided metastatic colorectal…
- Trial name
- NCT06547203
- Testing
- Cetuximab, Toripalimab, Irinotecan
- Where
- China
- Volunteers
- 34 people
- Sponsor
- Sun Yat-sen University
Metastatic Colorectal Cancer
Identification of Predictive Biomarker of Regorafenib in Refractory Colorectal Cancer
Regorafenib is a valuable treatment option for metastatic colorectal cancer patients who have progressed after prior standard treatments.
- Trial name
- NCT01996969
- Testing
- Regorafenib
- Where
- South Korea
- Volunteers
- 117 people
- Sponsor
- Seoul National University Hospital
Refractory Colorectal Adenocarcinoma
caBozantinib in Pre-treated pAtients With Metastatic COlorectal Cancer.
This is a phase II non-randomised and non-comparative study, in pretreated mCRC patients, progressed after at least 2 lines of prior chemotherapy for metastatic disease.
- Trial name
- ABACO (NCT06171854)
- Testing
- Cabozantinib
- Where
- Italy
- Volunteers
- 33 people
- Sponsor
- University of Campania Luigi Vanvitelli
Colorectal Carcinoma
A Trial of JX-594 in Refractory Colorectal Carcinoma
The purpose of this study is to: determine the maximally-tolerated dose (MTD) and/or maximum-feasible dose (MFD) of JX-594 administered by biweekly intravenous (IV) infusion.
- Trial name
- NCT01469611
- Testing
- JX-594
- Where
- South Korea
- Volunteers
- 15 people
- Sponsor
- Samsung Medical Center
Colorectal Cancer, Colon Cancer
Safety Study of 90Y-hMN14 to Treat Colorectal Cancer
The purpose of this trial is to determine the safety of 90Y-hMN14 at different dose levels in the treatment of colorectal cancer.
- Conditions
- Colorectal Cancer, Colon Cancer, Rectal Cancer, Colorectal Neoplasms
- Trial name
- NCT00040599
- Testing
- hMN14 (labetuzumab)
- Where
- 10 sites in United States, Germany and 3 more
- Volunteers
- 72 people
- Sponsor
- Gilead Sciences
Cancer
Natural History Study of Fungal Infections of the Blood in Patients With Cancer or in Patients Who Have Undergone a Stem Cell Transplant
RATIONALE: Gathering information about how often fungal infections of the blood occur in patients with cancer or in patients who have undergone stem cell transplant may help doctors learn more about the disease.
- Trial name
- NCT00445952
- Testing
- clinical observation, management of therapy complications
- Where
- 5 sites in Belgium, France and 3 more
- Volunteers
- 304 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Metastatic Colorectal Cancer
Dual Inhibition of EGFR Signalling Using the Combination of Cetuximab and Erlotinib
This is a clinical trial investigating the effectiveness and safety of the combination of the study drugs cetuximab and erlotinib in patients with advanced (metastatic) refractory colorectal (bowel) cancer.
- Trial name
- Dux (NCT00784667)
- Testing
- Cetuximab, Erlotinib
- Where
- 4 sites in Australia
- Volunteers
- 50 people
- Sponsor
- Austin Health
Colorectal Cancer
Everolimus in CDK12-Deficient Metastatic Colorectal Cancer (EVER-RECODE)
This is a prospective, open-label, multicenter, single-arm Phase Ib/II study evaluating the safety and preliminary efficacy of everolimus in patients with CDK12-deficient refractory metastatic colorectal cancer.
- Trial name
- EVER-RECODE (NCT07435584)
- Testing
- Everolimus (Afinitor) tablets
- Volunteers
- 38 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Solid Tumor, Adult, Epithelial Ovarian Cancer
Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors
This is a first-in-human, Phase 1/2 open-label, multicenter, dose-escalation, safety, pharmacokinetics (PK), and biomarker study of CBX-12 in subjects with advanced or metastatic refractory solid tumors.
- Conditions
- Solid Tumor, Adult, Epithelial Ovarian Cancer, Small Cell Lung Carcinoma, Breast Cancer
- Trial name
- NCT04902872
- Testing
- CBX-12
- Where
- 4 sites in United States
- Volunteers
- 69 people
- Sponsor
- Cybrexa Therapeutics
Refractory Metastatic Colorectal Cancer
A Phase Ib/III Study of Suvemcitug Plus FTD/TPI in Participants With Refractory Metastatic Colorectal Cancer
The primary goal of Phase Ib Study is to evaluate the safety of Suvemcitug in combination with trifluridine/tipiracil tablets in colorectal cancer participants.
- Trial name
- NCT07361003
- Testing
- Suvemcitug injection, trifluridine/tipiracil tablets
- Where
- 6 sites in China
- Volunteers
- 464 people
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
Human Papillomavirus-16 Positive, Human Papillomavirus-18 Positive
DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers
This phase II trial studies how well deoxyribonucleic acid (DNA) plasmid-encoding interleukin-12/human papillomavirus (HPV) DNA plasmids therapeutic vaccine INO-3112 and durvalumab work in treating patients with human…
- Conditions
- Human Papillomavirus-16 Positive, Human Papillomavirus-18 Positive, Metastatic Malignant Neoplasm, Recurrent Anal Canal Carcinoma
- Trial name
- NCT03439085
- Testing
- DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine MEDI0457, Durvalumab
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- M.D. Anderson Cancer Center
Colon Cancer
Fruquintinib In Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies in South Korea Patients (FIRST-K)
Background Patients with metastatic colorectal cancer who have progressed after treatment with oxaliplatin- and irinotecan-based chemotherapy, as well as anti-EGFR monoclonal antibodies (cetuximab or panitumumab) according to RAS…
- Trial name
- FIRST-K (NCT07510932)
- Testing
- Fruquintinib
- Volunteers
- 88 people
- Sponsor
- Korea University Anam Hospital
Metastatic Colorectal Cancer
Study of IMMU-130 in Patients With Relapsed/Refractory Colorectal Cancer
This is a Phase I trial to study the safety of IMMU-130. IMMU-130 is composed of a drug attached to an antibody. The drug is the active ingredient in irinotecan which is a common chemotherapy drug used for colorectal cancer.
- Trial name
- NCT01270698
- Testing
- IMMU-130
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Gilead Sciences